
ArchCath develops the investigational GateKeeper® Catheter, an embolic-protection medical device designed to reduce stroke risk during transcatheter aortic valve replacement (TAVR) and related complex cardiovascular procedures. The company reports early human testing and continued development toward larger clinical trials. Its goal is to improve procedural safety and reduce stroke-related complications; the device is not FDA approved or commercially available.
ArchCath hasn't reviewed it yet. Once they claim the page, every detail here is theirs to correct.
ArchCath hasn't claimed this page yet. Kindr doesn't accept donations for an organization until it has claimed its page and confirmed the details.
Comments
Log in to comment
Join the conversation with a Kindr account — creating one takes a minute.